Back to top
more

Myomo (MYO)

(Delayed Data from AMEX)

$3.64 USD

3.64
89,060

-0.19 (-4.96%)

Updated May 13, 2024 04:00 PM ET

After-Market: $3.62 -0.02 (-0.55%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for MYO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Myomo, Inc. [MYO]

Reports for Purchase

Showing records 81 - 100 ( 118 total )

Company: Myomo, Inc.

Industry: Medical - Products

Record: 81

05/13/2019

Company Report

Pages: 8

1Q:19 Sales Grew 165%, Year Over Year; Estimate Improved Reimbursement And Expanded

Provider: SIDOTI CSR

Analyst: Research Department

Price: .00

Research Provided by a Third Party

Company: Myomo, Inc.

Industry: Medical - Products

Record: 82

04/18/2019

Company Report

Pages: 8

Mirroring Our Expectation For 1Q:19, We Expect Expanding Reimbursement And Distribution Will

Provider: SIDOTI CSR

Analyst: Research Department

Price: .00

Research Provided by a Third Party

Company: Myomo, Inc.

Industry: Medical - Products

Record: 83

03/11/2019

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Myomo, Inc.

Industry: Medical - Products

Record: 84

03/11/2019

Company Report

Pages: 6

4Q18 Recap - Optimistic for 2019

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Myomo, Inc.

Industry: Medical - Products

Record: 85

03/08/2019

Company Report

Pages: 8

4Q:18 Sales Grew 63%, Year Over Year,Maintain $4 Price Target

Provider: SIDOTI CSR

Analyst: Research Department

Price: .00

Research Provided by a Third Party

Company: Myomo, Inc.

Industry: Medical - Products

Record: 86

02/08/2019

Company Report

Pages: 8

MYO Plans To Raise $6 Million Through An Equity Offering; Adjust Loss-Per-Share Estimates For

Provider: SIDOTI CSR

Analyst: Research Department

Price: .00

Research Provided by a Third Party

Company: Myomo, Inc.

Industry: Medical - Products

Record: 87

02/05/2019

Company Report

Pages: 4

We are transferring lead coverage to Scott Henry due to the departure of the lead-covering analyst

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Myomo, Inc.

Industry: Medical - Products

Record: 88

02/05/2019

Daily Note

Pages: 3

We are transferring coverage, placing Under Review, and removing PT''s and estimates

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Myomo, Inc.

Industry: Medical - Products

Record: 89

01/25/2019

Company Report

Pages: 8

Estimate Improved Reimbursement And Expanded Distribution Will Fuel About A 75% Sales CAGR

Provider: SIDOTI CSR

Analyst: Research Department

Price: .00

Research Provided by a Third Party

Company: Myomo, Inc.

Industry: Medical - Products

Record: 90

12/27/2018

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Myomo, Inc.

Industry: Medical - Products

Record: 91

12/24/2018

Company Report

Pages: 5

Blocking - Tackling in ''18 Could Pave the Way for an Inflection in ''19

Provider: Roth Capital Partners, Inc.

Analyst: SOLOMON D

Price: 10.00

Research Provided by a Third Party

Company: Myomo, Inc.

Industry: Medical - Products

Record: 92

12/19/2018

Company Report

Pages: 8

Forecast Improved Reimbursement And Expanding Distribution Will Fuel About 75% Average

Provider: SIDOTI CSR

Analyst: Research Department

Price: .00

Research Provided by a Third Party

Company: Myomo, Inc.

Industry: Medical - Products

Record: 93

11/08/2018

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Myomo, Inc.

Industry: Medical - Products

Record: 94

11/08/2018

Company Report

Pages: 7

3Q18 Miss, But CMS Codes Approved

Provider: Roth Capital Partners, Inc.

Analyst: SOLOMON D

Price: 25.00

Research Provided by a Third Party

Company: Myomo, Inc.

Industry: Medical - Products

Record: 95

11/06/2018

Company Report

Pages: 8

Reported 3Q:18 Sales Grew 25%; Estimate Improved Reimbursement And Expanded Distribution

Provider: SIDOTI CSR

Analyst: Research Department

Price: .00

Research Provided by a Third Party

Company: Myomo, Inc.

Industry: Medical - Products

Record: 96

10/30/2018

Company Report

Pages: 8

Estimate Improved Reimbursement And Expanded Distribution Will Fuel About 75% Average Sales

Provider: SIDOTI CSR

Analyst: Research Department

Price: .00

Research Provided by a Third Party

Company: Myomo, Inc.

Industry: Medical - Products

Record: 97

09/29/2018

Company Report

Pages: 4

We are dropping coverage on Myomo, Inc. to better allocate resources within our coverage universe.

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAYAL A

Price: 10.00

Research Provided by a Third Party

Company: Myomo, Inc.

Industry: Medical - Products

Record: 98

09/19/2018

Company Report

Pages: 8

We estimate sales will rise at about a 75% CAGR in the next three years.

Provider: SIDOTI CSR

Analyst: Research Department

Price: .00

Research Provided by a Third Party

Company: Myomo, Inc.

Industry: Unclassified

Record: 99

08/14/2018

Company Report

Pages: 4

Revenues Scaling; 2Q18 Results Overview

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAYAL A

Price: 10.00

Research Provided by a Third Party

Company: Myomo, Inc.

Industry: Medical - Products

Record: 100

08/08/2018

Company Report

Pages: 8

2Q:18 Sales More Than Doubled; Estimate Improved Reimbursement, Expanded Distribution Will

Provider: SIDOTI CSR

Analyst: Research Department

Price: .00

Research Provided by a Third Party